Seattle Genetics | search
Click here to view Seattle Genetics news from 60+ newspapers.
Bookmark or Share- Seagen - Seattle Genetics and CuraGen Expand Antibody-Drug Conjugate ...Feb. 15, 2005-Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that CuraGen Corporation (Nasdaq:CRGN) has exercised its option to designate a second antigen target under the parties' existing antibody-drug conjugate (ADC) collaboration, triggering a $1.0 million payment to Seattle Genetics.
- Seagen - Seattle Genetics to Present at the C.E. Unterberg, Towbin ...The company is conducting multiple clinical trials of its three lead product candidates, SGN-30, SGN-40 and SGN-33, and preclinical development of several late-stage programs, including SGN-35. In addition, Seattle Genetics has developed proprietary antibody-drug conjugate (ADC) technology comprised of
- Seattle Genetics to Present at JPMorgan Healthcare ConferenceJan. 6, 2005-Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the 23rd Annual JPMorgan Healthcare Conference on Wednesday, January 12, 2005, at 2:00 p.m. Pacific time.
- Seattle Genetics to Present at Upcoming Investor ConferencesMay 25, 2007-Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will present at two upcoming investor conferences. The presentations will be webcast live and available for replay from the Seattle Genetics website, www.seattlegenetics.com, under the "news and investor information" section.
- Seattle Genetics to Present at the BIO 2006 ConventionAbout Seattle Genetics Seattle Genetics is a biotechnology company focused on the development of monoclonal antibody-based therapies for the treatment of cancer and immunologic diseases. The company is conducting multiple clinical trials of its three lead product candidates, SGN-30, SGN-40 and SGN-33, and preclinical development of several
More
